062 - Treatments from Gilead and Regeneron Move Forward in Battle Against COVID-19!
05/03/20 • 32 min
Gilead's (#GILD) Remdesivir shows mixed results in 4 separate studies looking at treating COVID-19. The NIAID study has the most promise with a slight benefit in survival and significant benefit in time to recovery. Regeneron's (#REGN) Kevzara on the other hand, has now been limited to "critical" COVID-19 patients and we should see a phase 3 read out in June, 2020. I go in greater detail on Regeneron because despite not having a top COVID-19 treatment, they offer significant value to patients across the pharmaceutical landscape.
AXSM #Biotech
Follow me on twitter @matthewlepoire Send me an email [email protected] www.breakingbiotech.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech
Gilead's (#GILD) Remdesivir shows mixed results in 4 separate studies looking at treating COVID-19. The NIAID study has the most promise with a slight benefit in survival and significant benefit in time to recovery. Regeneron's (#REGN) Kevzara on the other hand, has now been limited to "critical" COVID-19 patients and we should see a phase 3 read out in June, 2020. I go in greater detail on Regeneron because despite not having a top COVID-19 treatment, they offer significant value to patients across the pharmaceutical landscape.
AXSM #Biotech
Follow me on twitter @matthewlepoire Send me an email [email protected] www.breakingbiotech.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech
Previous Episode
061 - Gilead's Remdesivir Efficacy Still Uncertain! Is Stemline Therapeutics a Buy?
In this video, I talk about the New England Journal of Medicine study published by Gilead (#GILD) on the compassionate use of Remdesivir for COVID-19. I also touch on the Statnews article about the leaked information regarding their upcoming Phase 3 trials. Finally, I talk about a great buying opportunity in the company Stemline Therapeutics (#STML). They have an approved drug, Elzonris, that is currently being studied in multiple other indications, if successful, will significantly increase the current stock price.
biotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech
Next Episode
063 - Biotech Updates (Including NASH follow up) STML TGTX SAVA SRNE TRIL MRKR GNFT CBAY
Hey everybody! In this video, I catch up on a variety of biotech companies. Timestamps for the respective company are below: STML 2:44 TGTX 4:29 SAVA 6:27 SRNE 11:27 TRIL/MRKR 15:15 GNFT/CBAY 20:55
If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotech You can also open an account at Tastyworks using my referral code here: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ
Follow me on twitter @matthewlepoire Send me an email [email protected] www.breakingbiotech.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/breaking-biotech-130757/062-treatments-from-gilead-and-regeneron-move-forward-in-battle-agains-6467864"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 062 - treatments from gilead and regeneron move forward in battle against covid-19! on goodpods" style="width: 225px" /> </a>
Copy